Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 32-year-old woman is evaluated in the neurology clinic to discuss ongoing management of relapsing-remitting multiple sclerosis. Over the past 14 months, she has experienced two disabling clinical relapses while on daily subcutaneous glatiramer acetate. Recent magnetic resonance imaging of the brain and cervical spine reveals three new gadolinium-enhancing lesions. After discussing treatment options, the physician and patient agree to discontinue glatiramer acetate and initiate oral fingolimod. Her past medical history is notable only for mild asthma that is well-controlled with an as-needed albuterol inhaler. She takes no other medications. Vital signs are temperature 37.0°C (98.6°F), blood pressure 118/76 mmHg, pulse 72/min, and respirations 14/min. Which of the following monitoring or baseline assessment steps are required for this patient prior to or during the initiation of this new pharmacotherapy? (Select all that apply)

  1. In-clinic observation for at least 6 hours following the initial dose with baseline and post-dose electrocardiogramsCevap
  2. Baseline ophthalmologic evaluation with a dilated fundus examinationCevap
  3. Baseline pulmonary function testing with spirometryCevap
  4. D
    Baseline echocardiography to evaluate left ventricular ejection fraction
  5. E
    Routine serologic screening for John Cunningham (JC) virus antibodies

Cevap

The correct requirements include an in-clinic observation for 6 hours with electrocardiograms, a baseline ophthalmologic evaluation, and baseline spirometry due to the patient's asthma.
Fingolimod is a sphingosine 1-phosphate receptor modulator that requires stringent baseline and initiation monitoring. Because it can cause dose-dependent bradycardia and atrioventricular conduction delays, patients must be observed in the clinic for at least 6 hours after the first dose with baseline and post-observation electrocardiograms. It also increases the risk of macular edema, requiring a baseline dilated ophthalmologic evaluation. Furthermore, because fingolimod can cause a dose-dependent reduction in forced expiratory volume in 1 second (FEV1), baseline spirometry is required in patients with preexisting respiratory conditions, such as this patient's asthma.

Adım Adım Çözüm

1
Identify the newly prescribed therapy and the patient's comorbidities.
The patient is initiating fingolimod for relapsing-remitting multiple sclerosis and has a comorbid history of asthma.
Monitoring requirements are dictated by both the universal adverse effect profile of the specific drug and patient-specific risk factors.
2
Determine the universal baseline and initiation monitoring requirements for fingolimod.
Fingolimod universally requires first-dose observation for at least 6 hours with electrocardiographic monitoring due to the risk of bradycardia and AV block. It also requires a baseline ophthalmologic evaluation due to the risk of macular edema.
These steps are mandated for all patients to prevent life-threatening arrhythmias and irreversible visual loss.
3
Evaluate if the patient's comorbidities require additional, specific monitoring.
Because the patient has a history of asthma, baseline pulmonary function testing (spirometry) is required.
Fingolimod acts on sphingosine 1-phosphate receptors and can cause bronchospasm and a decline in FEV1, making baseline respiratory assessment critical for asthmatic patients.
4
Rule out monitoring parameters that belong to other therapies in this class.
Echocardiography (required for mitoxantrone) and JC virus antibody screening (required for natalizumab) are incorrect.
Confusing the distinct monitoring profiles of various multiple sclerosis therapies can lead to unnecessary testing and increased healthcare costs.

Anahtar Kavram

Initiation of fingolimod requires specific monitoring including a 6-hour first-dose cardiovascular observation, baseline ophthalmologic evaluation for macular edema, and baseline spirometry in patients with a history of asthma or COPD.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru